Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Carmell Therapeutics ( (CTCX) ) just unveiled an announcement.
Carmell Therapeutics announced that on January 20, 2025, Kendra Bracken-Ferguson departed from her role as Chief Executive Officer by mutual agreement. Following her departure, she entered a separation agreement with the company, receiving $150,000 over six months. On January 24, 2025, Rajiv Shukla was appointed as the new CEO while retaining his role as Executive Chairman, marking a leadership transition within the company.
More about Carmell Therapeutics
YTD Price Performance: -36.23%
Average Trading Volume: 7,079,735
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.25M
Learn more about CTCX stock on TipRanks’ Stock Analysis page.
